EVALUATION OF TISSUE BIOMARKERS FOR RENAL CELL CANCER

You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging I1 Apr 2018MP28-16 EVALUATION OF TISSUE BIOMARKERS FOR RENAL CELL CANCER Gande Li and E Abel Gande LiGande Li More articles by this author and E AbelE Abel More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.916AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Despite surgical intervention, 25 to 50% of patients treated for localized renal cell carcinoma (RCC) will move on to develop metastatic disease. Current strategies to identify patients at risk for recurrence use a variety of clinical and pathological variables with poor predictability. Unlike other types of cancers, there is currently no biomarker established for RCC. However, recent studies have identified a subset of proteins expressed in RCC that may predict outcomes. The purpose of this study is to evaluate tissue biomarkers for RCC recurrence and cancer mortality in patients treated surgically for localized disease. METHODS Clinical and pathological data were collected and analyzed for all patients in the study cohort. In the previous study, data were obtained for 216 patients with RCC who were treated with partial or radical nephrectomy at the University of Wisconsin Hospital from January 2000 to December 2005. The validation cohort contains approximately 155 new patients.Tissue biomarker data were collected. After quantifying protein expression of each tissue biomarker, univariate and multivariate analyses were used to evaluate the risk of RCC recurrence and mortality based on the biomarker expressions. The risk of RCC recurrence and mortality were also analyzed using the conventional methods described above, and the predictive accuracy of these methods was compared to that of the automated high-throughput method. RESULTS Clinical and pathological variables of 155 patients were analyzed. The median follow-up time was 50 months. 17 (10.9%) of these patients had disease recurrence, and 25 (16.1%) died from RCC. In terms of mortality, the hazard ratios (HRs) for nucleus and cytoplasm NF-kB are 79.80, 95% confidence interval (CI) [2.69, 2363.65] and 360.42, 95% CI [4.35, 29894.93], respectively. Nucleus HIF1a has an HR of 3.06, 95% CI [1.84, 5.08] for mortality. Pathologic stage 3/4 has HRs of 12.53, 95% CI [3.62, 43.39] and 28.01, 95% CI [6.27, 125.17] for recurrence and mortality, respectively. CONCLUSIONS Compared to traditional variables, tissue biomarker NF-kB showed greater predictive values for RCC mortality. Results from HIF1a also suggests that it could be useful in predicting RCC mortality. However, both NF-kB and HIF1a have a limitation in the variability of their predictive values, possibly due to the small patient sample size and RCC heterogeneity, and they also did not show positive predictive values for cancer recurrence. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e362-e363 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Gande Li More articles by this author E Abel More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...